Two Sigma Investments LP Sells 4,635,617 Shares of Bristol-Myers Squibb (NYSE:BMY)

Two Sigma Investments LP trimmed its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 98.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 85,624 shares of the biopharmaceutical company's stock after selling 4,635,617 shares during the quarter. Two Sigma Investments LP's holdings in Bristol-Myers Squibb were worth $4,843,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of BMY. LaFleur & Godfrey LLC grew its holdings in Bristol-Myers Squibb by 3.5% in the 4th quarter. LaFleur & Godfrey LLC now owns 43,551 shares of the biopharmaceutical company's stock worth $2,463,000 after acquiring an additional 1,487 shares during the last quarter. Brighton Jones LLC grew its stake in shares of Bristol-Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock worth $1,116,000 after purchasing an additional 4,935 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its holdings in Bristol-Myers Squibb by 14.1% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 20,036 shares of the biopharmaceutical company's stock valued at $1,133,000 after purchasing an additional 2,469 shares during the period. Blue Trust Inc. raised its position in Bristol-Myers Squibb by 34.4% during the 4th quarter. Blue Trust Inc. now owns 34,273 shares of the biopharmaceutical company's stock valued at $1,773,000 after purchasing an additional 8,772 shares during the last quarter. Finally, Union Bancaire Privee UBP SA purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $312,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Stock Up 0.9%

Bristol-Myers Squibb stock traded up $0.41 during mid-day trading on Friday, hitting $48.26. The company had a trading volume of 20,756,575 shares, compared to its average volume of 13,069,665. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The stock's 50 day moving average price is $50.49 and its two-hundred day moving average price is $55.34. The company has a market capitalization of $98.21 billion, a PE ratio of -10.92, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. Bristol-Myers Squibb's revenue was down 5.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($4.40) EPS. As a group, sell-side analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.14%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb's payout ratio is 92.88%.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of the business's stock in a transaction on Friday, April 25th. The shares were acquired at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president now owns 83,513 shares in the company, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.09% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts recently weighed in on BMY shares. Cantor Fitzgerald reiterated a "neutral" rating and issued a $55.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. UBS Group cut their target price on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research note on Friday, April 11th. Argus upgraded shares of Bristol-Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Wells Fargo & Company raised their price objective on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a report on Friday, February 7th. Finally, William Blair reiterated a "market perform" rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Bristol-Myers Squibb currently has an average rating of "Hold" and a consensus target price of $58.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.